Results 11 to 20 of about 5,620 (149)

Amide proton transfer-weighted imaging of pediatric brainstem glioma and its predicted value for H3 K27 alteration [PDF]

Acta Radiologica, 2023
BACKGROUND: Non-invasive determination of H3 K27 alteration of pediatric brainstem glioma (pedBSG) remains a clinical challenge. PURPOSE: To predict H3 K27-altered pedBSG using amide proton transfer-weighted (APTw) imaging.
Barkhof, Frederik, Cheng, Dan, Duan, Yunyun, Haller, Sven, Liu, Xing, Liu, Yaou, Qu, Liying, Xie, Cong, Xu, Xiaolu, Zhang, Liwei, Zhang, Peng, Zhuo, Zhizheng   +11 more
core   +5 more sources

An exceptionally rare case of a diffuse midline glioma with concomitant H3.1 K27M and G34R mutations in the HIST1H3C (H3C3) gene [PDF]

Acta Neuropathologica Communications
Histone mutations (H3 K27M, H3 G34R/V) are molecular features defining subtypes of paediatric-type diffuse high-grade gliomas (HGG) (diffuse midline glioma (DMG), H3 K27-altered, diffuse hemispheric glioma (DHG), H3 G34-mutant).
Zita Reisz, Rita Pereira, Smitha Nevis, Alan Mackay, Leena Bhaw, Yura Grabovska, Ross Laxton, Valeria Molinari, Anna Burford, Barnaby Clark, Cristina Bleil, Bassel Zebian, Erika Pace, Annette Weiser, Fernando Carceller, Lynley Marshall, Andrew King, Istvan Bodi, Safa Al-Sarraj, Chris Jones, Matthew Clarke   +20 more
doaj   +2 more sources

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies. [PDF]

Expert Opin Ther Targets, 2023
H3 K27-altered diffuse midline glioma (DMG) is the most common malignant brainstem tumor in the pediatric population. Despite enormous preclinical and clinical efforts, the prognosis remains dismal, with fewer than 10% of patients surviving for two years after diagnosis.
Rechberger JS, Bouchal SM, Power EA, Nonnenbroich LF, Nesvick CL, Daniels DJ.   +5 more
europepmc   +3 more sources

Adult H3 K27-altered, H3.3 K27-mutant diffuse midline glioma affecting the conus medullaris: illustrative case. [PDF]

J Neurosurg Case Lessons
BACKGROUND Diffuse midline glioma (DMG) H3 K27–altered is a rare CNS tumor that predominantly affects midline structures in children. A relatively new subtype of glioma, it was first classified in 2016 and was further expanded in 2021 to include 4 molecular subtypes.
Sincari A, Yousif S, Robertson T, Huang YT, Alexander H.   +4 more
europepmc   +3 more sources

10179-NI-8 CLINICORADIOLOGICAL CHARACTERISTICS OF H3 K27-ALTERED THALAMIC GLIOMAS [PDF]

Neurooncol Adv, 2023
Abstract BACKGROUND Diffuse midline glioma (DMG), H3 K27-altered (CNS WHO grade 4, 2021), exhibits diverse imaging features, and its characteristics have not yet been established. METHODS We retrospectively analyzed the imaging ...
Hayashi, Nobuhide, Fukai, Junya, Nakatogawa, Hirokazu, Kawaji, Hiroshi, Okita, Yoshiko, Kijima, Noriyuki, Shofuda, Tomoko, Yoshioka, Ema, Kanematsu, Daisuke, Katsuma, Asako, Sumida, Miho, Nakao, Naoyuki, Mori, Kanji, Kanemura, Yonehiro   +13 more
europepmc   +2 more sources

H3 K27-altered diffuse midline glioma of the thalamus with formation of glio-fibrillary globular structures. [PDF]

Int J Clin Exp Pathol
A case of diffuse midline glioma (DMG), H3 K27-altered, that arose in the right thalamus of a 14-year-old boy is reported. The patient died of tumor spread after a progressive clinical course of approximately 13 months. Histopathologically, the tumor consisted of a mixture of loose proliferation of stellate cells and compact fascicular growth of ...
Shintaku M, Hashiba T, Nonaka M, Asai A, Tsuta K.   +4 more
europepmc   +3 more sources

H3 K27M-Altered Diffuse Midline Gliomas: A Review

Indian Journal of Neurosurgery, 2023
Diffuse midline glioma H3 K27M-altered is a recently renamed high-grade glioma in the 2021 World Health Organization (WHO) Classification of Central Nervous System Tumors, previously being labelled diffuse midline glioma H3 K27M-mutant in the 2016 update
Karol Wiśniewski, Andrew Ghaly, Kate Drummond, Andreas Fahlstrӧm   +3 more
doaj   +1 more source

Ara-C suppresses H3 K27-altered spinal cord diffuse midline glioma growth and enhances immune checkpoint blockade sensitivity. [PDF]

Sci Adv
H3 K27–altered spinal cord diffuse midline glioma (H3-SCDMG) poses therapeutic challenges. Analysis of 73 clinical samples revealed heightened proliferation in H3-SCDMG versus wild-type tumors, suggesting therapeutic vulnerabilities. Drug screening identified cytarabine (Ara-C) as highly effective in inhibiting proliferation in H3 K27M cell models ...
Pang B, Wu Y, An S, Chang Y, Yan H, Lin H, Zhao Z, Wu F, Chang Q, Jia W, Jiang T, Wang Y, Chai R.   +12 more
europepmc   +3 more sources

Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis

Acta Neuropathologica Communications, 2022
Posterior fossa group A ependymomas (EPN_PFA) are characterized by a loss of H3 K27 trimethylation due to either EZHIP overexpression or H3 p.K27M mutation, similar to H3 K27-altered diffuse midline gliomas (DMG), but in reverse proportions.
Cassandra Mariet, David Castel, Jacques Grill, Raphaël Saffroy, Volodia Dangouloff-Ros, Nathalie Boddaert, Francisco Llamas-Guttierrez, Céline Chappé, Stéphanie Puget, Lauren Hasty, Fabrice Chrétien, Alice Métais, Pascale Varlet, Arnault Tauziède-Espariat   +13 more
doaj   +1 more source

A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered. [PDF]

Neuro Oncol, 2023
Abstract Diffuse midline gliomas (DMGs) are devastating pediatric brain tumors recognized as the leading cause of cancer-related death in children. DMGs are high-grade gliomas (HGGs) diagnosed along the brain’s midline. Euchromatin is the hallmark feature of DMG, caused by global hypomethylation of H3K27 either through point mutations in
Jackson ER, Persson ML, Fish CJ, Findlay IJ, Mueller S, Nazarian J, Hulleman E, van der Lugt J, Duchatel RJ, Dun MD.   +9 more
europepmc   +3 more sources